Equities

SKAN Group AG

SKAN Group AG

Actions
  • Price (CHF)76.10
  • Today's Change-2.70 / -3.43%
  • Shares traded16.95k
  • 1 Year change+2.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 16:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SKAN Group AG, former BV Holding AG, is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.

  • Revenue in CHF (TTM)344.01m
  • Net income in CHF32.24m
  • Incorporated2001
  • Employees1.42k
  • Location
    SKAN Group AGKreuzstrasse 5ALLSCHWIL 4123SwitzerlandCHE
  • Phone+41 432683232
  • Fax+41 313801859
  • Websitehttps://skan.com/de/home/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GVS SpA398.92m23.71m953.34m4.39k39.942.8514.572.390.14570.14572.442.050.43032.006.1697,169.862.567.353.2510.8255.1258.745.9412.441.033.980.5461--9.5815.25-43.37-9.9716.08--
ChemoMetec A/S51.18m17.10m1.02bn173.0059.7114.3952.8419.957.837.8323.4432.480.61120.7456.972,357,630.0020.4227.9624.4035.1078.8079.5733.4135.023.76--0.0073144.08-8.2218.37-23.7226.649.97-11.81
Biotage AB171.54m20.73m1.03bn675.0049.823.3629.226.023.213.2126.5647.600.43121.597.223,155,786.005.2110.746.0512.7762.6761.4012.0815.751.1543.880.061640.1119.5415.50-8.217.9714.051.30
Xvivo Perfusion AB60.53m16.47m1.15bn161.0068.856.8551.7019.016.586.5824.0766.130.33251.144.674,691,194.009.051.249.681.3374.4173.1427.214.764.23--0.01170.0043.8826.04398.2948.5721.35--
AddLife AB807.45m9.44m1.28bn2.36k140.513.2115.151.590.96010.960182.1642.090.76253.505.584,351,152.000.90635.311.298.8337.3036.891.195.790.6381.660.514631.736.6231.30-60.428.0044.43-1.89
Oxford Nanopore Technologies PLC188.87m-179.09m1.54bn1.28k--2.17--8.16-0.187-0.1870.1970.6620.22650.73332.86135,499.20-21.47-21.12-24.63-24.6753.8953.90-94.82-81.853.36--0.0747---14.5739.15-69.74--8.92--
SKAN Group AG344.01m32.24m1.77bn1.42k55.2210.2338.215.151.431.4315.247.700.91790.684512.01247,846.509.037.5618.7814.9574.0773.249.849.630.581338.460.034124.0915.55118.7738.5935.49----
Elekta AB (publ)1.46bn91.37m1.89bn4.57k21.432.2710.141.292.962.9647.3828.010.58223.162.893,903,469.003.654.196.537.5136.7639.036.277.370.74253.910.419668.607.415.9838.071.6820.065.92
Embla Medical hf744.50m61.19m1.91bn4.00k31.422.7517.452.571.131.1313.7612.950.57552.236.651,483,676.004.754.065.514.7662.0262.478.256.911.266.590.40743.999.335.0937.34-6.056.50--
Medacta Group SA509.33m52.60m2.24bn1.83k42.576.9520.224.402.632.6325.4916.140.79080.855.62294,410.608.177.8910.3610.5767.9370.4310.3310.090.84511.020.401517.0116.8513.382.410.69378.32--
Gerresheimer AG1.88bn106.98m2.40bn12.01k22.411.798.241.273.313.3158.2641.470.58163.936.93172,572.903.363.314.604.7529.0929.725.785.940.46354.290.463442.689.547.7920.819.0023.421.68
Vitrolife AB286.63m-306.87m2.50bn1.10k--2.36--8.73-28.10-28.1026.2497.030.18673.486.483,293,791.00-19.99-4.57-20.71-4.7858.1658.38-107.03-21.892.369.240.135--8.6024.99-1,077.41---7.953.30
Data as of Nov 14 2024. Currency figures normalised to SKAN Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

23.73%Per cent of shares held by top holders
HolderShares% Held
J. Safra Sarasin Investmentfonds AGas of 31 Dec 2023785.00k3.49%
VV Verm�gensverwaltung AGas of 30 Aug 2024785.00k3.49%
Capital Research & Management Co. (World Investors)as of 30 Sep 2024759.39k3.38%
Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024682.80k3.04%
Pictet Asset Management SAas of 30 Jun 2024470.12k2.09%
UBS Asset Management Switzerland AGas of 30 Sep 2024452.82k2.01%
Threadneedle Asset Management Ltd.as of 30 Sep 2024431.04k1.92%
The Vanguard Group, Inc.as of 02 Oct 2024382.56k1.70%
Vontobel Asset Management AGas of 30 Sep 2024324.29k1.44%
Norges Bank Investment Managementas of 30 Jun 2024262.81k1.17%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.